EUVIMEDEUVIMED entdecken
Crossref

OPTIMIZATION OF THE COMPOSITION AND TECHNOLOGY OF AN ENCAPSULATED FORMULATION FOR THE MANAGEMENT OF LIVER DISORDERS WITH MONITORING OF BIOACTIVE COMPOUND STABILITY

Yu.R. Mukhametova, B. Tohiriyon

Bulletin of the South Ural State University Series Food and Biotechnology · 2026 · 14 (3) · 77-84

DOI: 10.14529/food260308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin of the South Ural State University Series Food and Biotechnology, 2026. Verfasst von Yu.R. Mukhametova und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present work considers an encapsulated composition based on polyprenols, silymarin, and essential phospholipids. The bioavailability was studied, and the technological parameters of its preparation were optimized. The object of the study was an encapsulated composition containing conifer polyprenols, silymarin (milk thistle extract), liquid lecithin, and tocopheryl acetate. The study was aimed at mathematical optimization of the process parameters for soft gelatin capsule manufacturing through one-way analysis of variance (ANOVA) and the desirability function, as well as experimental confirmation of the retention of biologically active substances (BAS) and their release profile under conditions simulating small-intestinal digestion. The variable factors included the lecithin mass fraction in the lipid phase (15–35 %), aerosil concentration (0,5–3.0 %), and the lipid base homogenization temperature (40–60 °C). It was established that consistent capsule quality (overall desirability criterion D ≥ 0.88) is maintained within the technologically acceptable ranges of lecithin 20–35%, aerosil 1.5–2.5 %, and temperature 42–50 °C. Given pilot-scale production requirements, the following working parameters were adopted: lecithin 22–33 %, aerosil 2.4 %, and temperature < 50 °C. A three-step algorithm for sequential introduction of heat-labile BAS with intermediate cooling of the lipid base was proposed; it ensures silymarin recovery of (95.4 ± 0.9)% and polyprenols recovery of (97.1 ± 0.7)%. In the dissolution test, the release of silybinin within 45 min in the medium simulating intestinal digestion reached (88.3 ± 2.5)%, which allows the developed formulation to be classified as rapidly releasing. The results confirm the previously adopted formulation decisions and provide a reproducible quality control tool for product scale-up.

Zitieren

APA

Mukhametova, Y., & Tohiriyon, B. (2026). OPTIMIZATION OF THE COMPOSITION AND TECHNOLOGY OF AN ENCAPSULATED FORMULATION FOR THE MANAGEMENT OF LIVER DISORDERS WITH MONITORING OF BIOACTIVE COMPOUND STABILITY. Bulletin of the South Ural State University Series Food and Biotechnology, 14(3), 77-84. https://doi.org/10.14529/food260308

Vancouver

Mukhametova Y, Tohiriyon B. OPTIMIZATION OF THE COMPOSITION AND TECHNOLOGY OF AN ENCAPSULATED FORMULATION FOR THE MANAGEMENT OF LIVER DISORDERS WITH MONITORING OF BIOACTIVE COMPOUND STABILITY. Bulletin of the South Ural State University Series Food and Biotechnology. 2026;14(3):77-84. doi:10.14529/food260308

BibTeX
@article{Mukhametova2026,
  author = {Mukhametova, Yu.R. and Tohiriyon, B.},
  title = {OPTIMIZATION OF THE COMPOSITION AND TECHNOLOGY OF AN ENCAPSULATED FORMULATION FOR THE MANAGEMENT OF LIVER DISORDERS WITH MONITORING OF BIOACTIVE COMPOUND STABILITY},
  journal = {Bulletin of the South Ural State University Series Food and Biotechnology},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {77--84},
  doi = {10.14529/food260308}
}
Kostenlos starten →